I am currently conducting a study on epigenetic biomarkers in prostate cancer, and I am particularly focusing on the methylation status of RASSF1. While reviewing the literature and designing my experiments, I have encountered some uncertainty regarding which RASSF1 isoforms would be most appropriate to assess for methylation in this context. Given your expertise and work in this field, I would be extremely grateful for any guidance or recommendations you could provide on selecting the most relevant isoforms for accurate and meaningful methylation analysis.
Thank you for your respond
Dear Dr. Mohammad Reza Lornejad-Schäfer
RASSF1A methylation is considered a promising biomarker for early detection, prognosis, and potential therapeutic monitoring of prostate cancer. RASSF1A functions as a tumor suppressor gene and its function is reduced or lost due to epigenetic modifications, primarily promoter hypermethylation.
Below are a few articles that will help.
Article The association between RASSF1A promoter methylation and pro...
Article Epigenetic Modifications of RASSF1A Gene through Chromatin R...
Article Association between RASSF1A Promoter Methylation and Prostat...
Regards,
Malcolm Nobre
Dear Dr. Malcolm Nobre
Thank you so much for your helpful response and for sharing the references. In our project, we are trying to design primers for RASSF1A. We used the EPD (Eukaryotic Promoter Database) to search for the promoter sequence, but we could only find RASSF1_1 to RASSF1_4, and there was no direct entry for RASSF1A. Could you please clarify whether RASSF1A corresponds to RASSF1-1 in the EPD database, or if it should be considered differently? If they are not the same, could you kindly advise how we can obtain the exact promoter sequence of RASSF1A?
best regards
Mohammad Reza Lornejad
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology